A phase 1 dose‐escalation study of XmAb®2513 in patients with relapsed or refractory Hodgkin lymphoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|168|6|902-904

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.168, Iss.6, 2015-03, pp. : 902-904

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase 1, open‐label, dose escalation, safety, and pharmacokinetics study of ME‐344 as a single agent in patients with refractory solid tumors

By  

CANCER, Vol. 121, Iss. 7, 2015-04 ,pp. : 1056-1063

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B‐cell non‐Hodgkin lymphoma: A Wisconsin Oncology Network study

By  

CANCER, Vol. 121, Iss. 19, 2015-10 ,pp. : 3465-3471

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase II trial of ofatumumab plus ESHAP (O‐ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first‐line chemotherapy

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 174, Iss. 6, 2016-09 ,pp. : 859-867

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B‐cell lymphoma: mature results of a phase II multicentre study

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 6, 2015-03 ,pp. : 824-834

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase 1B, randomized, double‐blind, dose‐escalation trial of CPG 10101 in patients with chronic hepatitis C virus

By  

HEPATOLOGY, Vol. 46, Iss. 5, 2007-11 ,pp. : 1341-1349

John Wiley & Sons Inc

Access to resources Recommend Favorite